KBC Group
NKTR icon

KBC Group’s Nektar Therapeutics NKTR Stock Holding History

KBC Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81K Buy
1,167
+446
+62% +$32.6K ﹤0.01% 1524
2026
Q1 		$52K Buy
+721
New +$41.1K ﹤0.01% 1634
2023
Q2 		– Sell
-1,082
Closed -$11K – 1507
2023
Q1 		$11K Hold
1,082
– – ﹤0.01% 1497
2022
Q4 		$37K Hold
1,082
– – ﹤0.01% 1451
2022
Q3 		$52K Hold
1,082
– – ﹤0.01% 1385
2022
Q2 		$62K Buy
1,082
+465
+75% +$29.3K ﹤0.01% 1380
2022
Q1 		$50K Buy
617
+46
+8% +$6.81K ﹤0.01% 1243
2021
Q4 		$116K Buy
571
+84
+17% +$18.2K ﹤0.01% 1155
2021
Q3 		$131K Hold
487
– – ﹤0.01% 1129
2021
Q2 		$125K Hold
487
– – ﹤0.01% 1145
2021
Q1 		$146K Hold
487
– – ﹤0.01% 1136
2020
Q4 		$124K Buy
487
+117
+32% +$30.2K ﹤0.01% 1132
2020
Q3 		$92K Sell
370
-4,750
-93% -$1.49M ﹤0.01% 1128
2020
Q2 		$1.78M Sell
5,120
-18,782
-79% -$5.86M 0.01% 581
2020
Q1 		$6.4M Sell
23,902
-7,072
-23% -$2.19M 0.05% 325
2019
Q4 		$10M Buy
30,974
+28,290
+1,054% +$8.2M 0.06% 322
2019
Q3 		$733K Buy
2,684
+1,691
+170% +$620K 0.01% 977
2019
Q2 		$530K Hold
993
– – ﹤0.01% 1051
2019
Q1 		$500K Buy
993
+198
+25% +$117K ﹤0.01% 1082
2018
Q4 		$392K Buy
795
+19
+2% +$11.5K ﹤0.01% 981
2018
Q3 		$710K Hold
776
– – 0.01% 1019
2018
Q2 		$569K Buy
+776
New +$895K ﹤0.01% 955
2018
Q1 		– Sell
-1,648
Closed -$1.48M – 1304
2017
Q4 		$1.48M Buy
+1,648
New +$975K 0.01% 669
2016
Q4 		– Sell
-3,161
Closed -$815K – 1323
2016
Q3 		$815K Buy
3,161
+1,700
+116% +$438K 0.01% 831
2016
Q2 		$312K Buy
+1,461
New +$327K ﹤0.01% 985

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's NKTR Position: Q2 2026 in Review

KBC Group increased its Nektar Therapeutics (NKTR) stake by 62% in Q2 2026, buying an estimated $32.6K and bringing the position to 1,167 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #1524.

KBC Group first reported a position in NKTR in Q2 2016 and has held it in 25 quarters since. The position peaked at $10M in Q4 2019. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • KBC Group held 1,167 shares of Nektar Therapeutics worth $81K as of Q2 2026.
  • KBC Group bought 446 Nektar Therapeutics shares in Q2 2026, an estimated $32.6K.
  • Nektar Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1524 holding.
  • KBC Group first reported a position in Nektar Therapeutics in Q2 2016 and has held it in 25 quarters since.
  • KBC Group's Nektar Therapeutics position peaked at $10M in Q4 2019.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.